<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01773967</url>
  </required_header>
  <id_info>
    <org_study_id>1R01HD071915</org_study_id>
    <nct_id>NCT01773967</nct_id>
    <nct_alias>NCT00970164</nct_alias>
  </id_info>
  <brief_title>Impact of Emergency Department Probiotic (LGG) Treatment of Pediatric Gastroenteritis</brief_title>
  <official_title>Impact of Emergency Department Probiotic (LGG) Treatment of Pediatric Gastroenteritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's National Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will study the efficacy and side effect profile of LGG, a probiotic, in
      pediatric patients with acute gastroenteritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter randomized controlled trial of LGG in patients 3-48 months of age presenting to
      the Emergency Department with acute gastroenteritis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2014</start_date>
  <completion_date type="Actual">August 2018</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Modified Vesikari Scale Score &gt;=9</measure>
    <time_frame>14 days</time_frame>
    <description>This is a validated gastroenteritis severity score that includes duration and frequency of diarrhea, duration and frequency of vomiting, duration and frequency of fever and use of health care resources. Scores &gt;=9 indicate moderate-severe gastroenteritis. Higher is worse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With LGG Bacteremia</measure>
    <time_frame>1 month</time_frame>
    <description>bacteremia caused by LGG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diarrhea Duration</measure>
    <time_frame>14 days</time_frame>
    <description>diarrhea duration in hours after randomization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">971</enrollment>
  <condition>Gastroenteritis</condition>
  <arm_group>
    <arm_group_label>LGG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LGG 10^10 cfu PO bid x 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>micro-crystalline cellulose PO bid x 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LGG</intervention_name>
    <description>LGG 10^10 cfu PO BID X 5 days</description>
    <arm_group_label>LGG</arm_group_label>
    <other_name>Lactobacillus GG ATCC 53103</other_name>
    <other_name>Lactobacillus rhamnosus</other_name>
    <other_name>culturelle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>micro-crystalline cellulose</intervention_name>
    <description>1 capsule PO bid x 5 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>placebo micro-crystalline cellulose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 3-48 months (have not yet reached their fourth birthday); AND

          2. Presence of 3 or more watery stools within 24 hours of screening; AND

          3. Duration of vomiting or diarrhea less than 7 days; AND

          4. Symptoms consistent with acute intestinal infectious process.

        Exclusion Criteria:

          1. Presence of an indwelling vascular access line; OR

          2. Presence of structural heart disease excluding non-pathological heart murmurs; OR

          3. Receiving immunosuppressive therapy or history of immunodeficiency; OR

          4. Hematochezia in the preceding 48 hours; OR

          5. Chronic gastrointestinal problems (e.g. short gut syndrome, inflammatory bowel
             disease); OR

          6. Patients with known pancreatitis; OR

          7. History of abdominal surgery; OR

          8. Critically ill patients; OR

          9. Family member with an indwelling vascular access line, or on immunosuppressive
             therapy, or with a known immunodeficiency; OR

         10. Bilious emesis; OR

         11. Probiotic use (supplement) in the preceding 2 weeks; OR

         12. Oral or intravenous steroid use in the preceding six months; OR

         13. Previously enrolled in this trial; OR

         14. Allergy to lactobacillus or Microcrystalline Cellulose (MCC); OR

         15. Allergy to erythromycin, clindamycin, AND betalactam antibiotics (all); OR

         16. Not available for daily follow-up while symptomatic; OR

         17. Parent/guardian not speaking English or Spanish; OR

         18. Under 6 months old AND premature (&lt;37 weeks).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>48 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberly Quayle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hasbro Children's Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>January 10, 2013</study_first_submitted>
  <study_first_submitted_qc>January 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2013</study_first_posted>
  <results_first_submitted>June 25, 2019</results_first_submitted>
  <results_first_submitted_qc>August 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 6, 2019</results_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lactobacillus rhamnosus GG</keyword>
  <keyword>LGG</keyword>
  <keyword>Probiotic</keyword>
  <keyword>Gastroenteritis</keyword>
  <keyword>acute gastroenteritis</keyword>
  <keyword>child</keyword>
  <keyword>pediatric</keyword>
  <keyword>RCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroenteritis</mesh_term>
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 6, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT01773967/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lactobacillus Rhamnosus GG</title>
          <description>LGG 10^10 cfu PO bid x 5 days
LGG: LGG 10^10 cfu PO BID X 5 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>micro-crystalline cellulose PO bid x 5 days
micro-crystalline cellulose: 1 capsule PO bid x 5 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="483"/>
                <participants group_id="P2" count="488"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="468"/>
                <participants group_id="P2" count="475"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lactobacillus Rhamnosus GG</title>
          <description>LGG 10^10 cfu PO bid x 5 days
LGG: LGG 10^10 cfu PO BID X 5 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>micro-crystalline cellulose PO bid x 5 days
micro-crystalline cellulose: 1 capsule PO bid x 5 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="483"/>
            <count group_id="B2" value="488"/>
            <count group_id="B3" value="971"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.4" lower_limit="0.9" upper_limit="2.4"/>
                    <measurement group_id="B2" value="1.4" lower_limit="0.8" upper_limit="2.3"/>
                    <measurement group_id="B3" value="1.4" lower_limit="0.9" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="236"/>
                    <measurement group_id="B2" value="222"/>
                    <measurement group_id="B3" value="458"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="247"/>
                    <measurement group_id="B2" value="266"/>
                    <measurement group_id="B3" value="513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="162"/>
                    <measurement group_id="B3" value="338"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="307"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="483"/>
                    <measurement group_id="B2" value="488"/>
                    <measurement group_id="B3" value="971"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Median Modified Vesikari Scale score at presentation</title>
          <description>The modified Vesikari scale is a validated global gastroenteritis severity scale that includes duration and severity of vomiting and diarrhea, maximum recorded temperature, unscheduled health care visits and types of treatment received. Scores range from 0 to 20, with higher scores indicating more severe disease). A score of 9 or greater is considred moderate to severe gastroenteritis</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12" lower_limit="10" upper_limit="14"/>
                    <measurement group_id="B2" value="12" lower_limit="9" upper_limit="14"/>
                    <measurement group_id="B3" value="12" lower_limit="10" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Modified Vesikari Scale Score &gt;=9</title>
        <description>This is a validated gastroenteritis severity score that includes duration and frequency of diarrhea, duration and frequency of vomiting, duration and frequency of fever and use of health care resources. Scores &gt;=9 indicate moderate-severe gastroenteritis. Higher is worse.</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lactobacillus Rhamnosus GG</title>
            <description>LGG 10^10 cfu PO bid x 5 days
LGG: LGG 10^10 cfu PO BID X 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>micro-crystalline cellulose PO bid x 5 days
micro-crystalline cellulose: 1 capsule PO bid x 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Modified Vesikari Scale Score &gt;=9</title>
          <description>This is a validated gastroenteritis severity score that includes duration and frequency of diarrhea, duration and frequency of vomiting, duration and frequency of fever and use of health care resources. Scores &gt;=9 indicate moderate-severe gastroenteritis. Higher is worse.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
                <count group_id="O2" value="475"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.83</p_value>
            <method>Mantel Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With LGG Bacteremia</title>
        <description>bacteremia caused by LGG</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lactobacillus Rhamnosus GG</title>
            <description>LGG 10^10 cfu PO bid x 5 days
LGG: LGG 10^10 cfu PO BID X 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>micro-crystalline cellulose PO bid x 5 days
micro-crystalline cellulose: 1 capsule PO bid x 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With LGG Bacteremia</title>
          <description>bacteremia caused by LGG</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
                <count group_id="O2" value="475"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diarrhea Duration</title>
        <description>diarrhea duration in hours after randomization</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lactobacillus Rhamnosus GG</title>
            <description>LGG 10^10 cfu PO bid x 5 days
LGG: LGG 10^10 cfu PO BID X 5 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>micro-crystalline cellulose PO bid x 5 days
micro-crystalline cellulose: 1 capsule PO bid x 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Diarrhea Duration</title>
          <description>diarrhea duration in hours after randomization</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
                <count group_id="O2" value="475"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.7" lower_limit="18.8" upper_limit="86.4"/>
                    <measurement group_id="O2" value="50.9" lower_limit="25.0" upper_limit="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>Van Elteren's modification Mann-Whitney</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>35 days, long term follow up 1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lactobacillus Rhamnosus GG</title>
          <description>LGG 10^10 cfu PO bid x 5 days
LGG: LGG 10^10 cfu PO BID X 5 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>micro-crystalline cellulose PO bid x 5 days
micro-crystalline cellulose: 1 capsule PO bid x 5 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="488"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="488"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="483"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="488"/>
              </event>
              <event>
                <sub_title>ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="488"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="488"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="488"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="488"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>metabolic acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="488"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>seizure</sub_title>
                <description>febrile</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="488"/>
              </event>
              <event>
                <sub_title>lethargy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="488"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>lower respiratory infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="488"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="483"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="488"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>other</sub_title>
                <counts group_id="E1" events="40" subjects_affected="40" subjects_at_risk="483"/>
                <counts group_id="E2" events="35" subjects_affected="35" subjects_at_risk="488"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>other</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="483"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="488"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David Schnadower</name_or_title>
      <organization>Cincinnati Children's Hospital Medical Center</organization>
      <phone>5138035526</phone>
      <email>david.schnadower@cchmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

